🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Si algun #mir2024 creu que li pot interessar l'especialitat de Farmacologia Clínica en general, i a l'Hospital Clínic en particular, que ens contacti! Som pocs i ningú sap ben bé què fem, però som majos. Lucía Arellano Joaquín Sáez Peñataro @victoriaanl_ Juan Cionaig Lina Leguízamo

En la SETGyC estamos orgullosos de contar con tantas científicas brillantes, entregadas a la investigación y con activa participación. Queremos dar un especial reconocimiento a todas las socias junior, investigadoras del presente y próximas referentes en las terapias avanzadas.

🔬 Durante la presentación se ha anunciado que, gracias al impulso del #ProjecteARI, se iniciará un ensayo con un CAR-T dual, el ARI-0003, para el tratamiento de #linfomas. 💊Participarán 3⃣5⃣ pacientes y empezará en las próximas semanas.

Memory genes are enriched in CAR T cells that persist and control tumors in patients. But which transcription factors drive beneficial memory programs? We answer this in our lab’s first paper in nature led by Alex Doan Kat Mueller, PhD Andy Chen. 1/ nature.com/articles/s4158…

Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma aacrjournals.org/clincancerres/…

Barcelona calling for the first multinational, fully academic, CART trial with the academic #ARI0001 (var-cel) CART19 for adult patients with high-risk / refractory B-ALL (CART19-EU-04 trial). This is, academic European institutions making a bit of history! 🤝 🇪🇦🇨🇵🇱🇺🇦🇹 +

💉 Overcoming T-cell inhibition via the PD-1/PD-L1 axis is a critical challenge in CAR-T cell therapy 📝 Our latest publication in Nature Communications unveils how CAR-antigen affinity could pivotally influence T-cell susceptibility to this axis ⬇️

We are looking for a motivated PhD candidate to start researching in CAR-T cell immunotherapy. Initially, we offer a 6-month contract to learn and to apply during that time to additional grants to do the PhD. For additional information: fjd.es/iis-fjd/es/for…

💉 In collaboration with SETGyC, our colleagues from HospitalUVRocio and IBiS are organizing the PhD training day "CARTcell: from bench to bedside" in Seville on Sep 19-20. ✈️ From the SETGyC, we are offering 15 travel grants. Take a look! ➡️ setgyc.es/sevilla2024

Today, FDA expanded the approval of a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene. fda.gov/news-events/pr…

Today, at TLH, we summarise a decade of hard work. We wish to thank all colleagues, patients and relatives, who helped us during this amazing journey. thelancet.com/journals/lanha…

🔬 L’Hospital Clínic-IDIBAPS ha iniciat un #assaigclínic amb l’ARI-0003 per a limfoma. L’avantatge amb aquest CAR-T és que s’ha dissenyat amb diversos centres, i per tant tindrà una distribució més alta. 🤝 Col·labora amb el #ProjecteARI 👉 lnkd.in/dpVXkbgA

🏥 Luz verde al CAR-T ARI0002h desarrollado por el #CLÍNIC-IDIBAPS para pacientes con #mielomamúltiple en recaída. ✅ El Comité de AEMPS ha dado el visto bueno para aprobarlo como medicamento de terapia avanzada de fabricación no industrial. 👉 clinicbarcelona.org/noticias/luz-v…

On Friday, Nov. 8, FDA approved #obecel for B-cell #acutelymphoblasticleukemia (#ALL) Obe-cel is a CD19 CAR T-cell investigational therapy designed with a fast target binding off-rate to minimize excessive activation of the programmed T cells. lnkd.in/gzJFSTrR

Check out our new paper in Molecular Therapy! Congrats Mireia Bachiller and Nina for the hard work 💪🏽💪🏽

Our work is now published in Molecular Therapy! Here we characterize ARI0003, a co-transduced CAR-T cell therapy targeting CD19/BCMA for B-NHL. Special thanks to my mentors SoniaGuedan and Alvaro Urbano-Ispizua, and to my amazing co-authors Nina Barceló and Alba Rodríguez.

Bye bye, bispecific? Check out our commentary on the development of a CD19/BCMA dual targeting CAR-T for non-Hodgkin Lymphoma led by Bachiller et al. SoniaGuedan Molecular Therapy Co-transduction for the win! Link below ⬇️ for free access authors.elsevier.com/a/1kIWB5QliS5B…… Claire Roddie

🏥 This therapy developed at IDIBAPS is now in clinical trials at Hospital Clínic de Barcelona. We hope this contributes not only to advancing research but also to making CAR-T cell therapy more understandable and accessible. Together, we keep moving forward!

💉 For those colleagues attending the 7th European CAR T-cell Meeting of the European Hematology Association and The EBMT in 🇫🇷 Strasbourg, I’ll be presenting Next-generation CAR-T cells for solid tumors and hematological malignancies in Room Schweitzer, from 9:30 to 10:30 h. Come say hi!